Literature DB >> 11009201

Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene.

R J Carter1, M J Hunt, A J Morton.   

Abstract

Mice transgenic for the first exon of the human Huntington's disease (HD) gene carrying an expanded CAG repeat expansion (R6/2 line) develop a progressive neurologic phenotype with symptoms resembling those seen in HD. The overt symptoms of R6/2 mice worsen with age, resulting in a rapid decline in health and premature death between 13 and 18 weeks of age. In this study, we characterized the onset and progression of the overt phenotype in R6/2 mice and examined factors that affect the phenotype and life expectancy of these mice. In particular, the effects of altering home cage environment, through changing feeding regimes and providing environmental stimulation, were investigated. We show that changes in feeding regimes significantly improved the general well-being and life expectancy of R6/2 mice. Furthermore, we find that various forms of environmental stimulation, including regular behavioral testing, significantly improved the survival of R6/2 mice over and above that resulting from the enhanced feeding regime. The fact that environmental stimulation improves the health and life expectancy in R6/2 mice not only enables the mice to serve as more useful research tools, but also suggests that environmental stimulation may have a beneficial impact on the progression of HD in patients.

Entities:  

Mesh:

Year:  2000        PMID: 11009201     DOI: 10.1002/1531-8257(200009)15:5<925::aid-mds1025>3.0.co;2-z

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

Review 1.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 2.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 3.  Stem Cells Transplantation and Huntington's Disease.

Authors:  Wooseok Im; Soon-Tae Lee; Kon Chu; Manho Kim; Jae-Kyu Roh
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

4.  BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.

Authors:  A Reiner; H B Wang; N Del Mar; K Sakata; W Yoo; Y P Deng
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

5.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

Review 6.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

7.  Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.

Authors:  Mark J Hunt; A Jennifer Morton
Journal:  Exp Brain Res       Date:  2005-07-21       Impact factor: 1.972

Review 8.  The corticostriatal pathway in Huntington's disease.

Authors:  Carlos Cepeda; Nanping Wu; Véronique M André; Damian M Cummings; Michael S Levine
Journal:  Prog Neurobiol       Date:  2006-12-13       Impact factor: 11.685

9.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

10.  Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease.

Authors:  Patrick N Pallier; Elizabeth S Maywood; Zhiguang Zheng; Johanna E Chesham; Alexei N Inyushkin; Richard Dyball; Michael H Hastings; A Jennifer Morton
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.